|
|
|
Insider
Information: |
Singh Shawn |
Relationship: |
|
City: |
Franklin |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
6,858 |
|
Indirect Shares
|
20,875 |
|
|
Direct
Value |
$22,138 |
|
|
Indirect Value
|
$82,039 |
|
|
Total
Shares |
27,733 |
|
|
Total
Value |
$104,177 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
Percentage
Gain/Loss : |
-36.3%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Echo Therapeutics Inc |
ECTE |
Director |
2009-02-20 |
1,225 |
2007-09-14 |
0 |
Premium* |
|
Vistagen Therapeutics Inc |
VTGN |
|
2023-12-29 |
5,633 |
2023-12-29 |
20,875 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
19 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ECTE |
Echo Therapeutics Inc |
President (Interim) |
|
2007-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
625,907 |
625,907 |
0 |
- |
|
ECTE |
Echo Therapeutics Inc |
Director |
|
2009-02-20 |
5 |
A |
$0.00 |
$0 |
D/D |
100,000 |
1,226 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2011-05-11 |
4 |
A |
$3.50 |
$266,305 |
I/I |
76,087 |
76,087 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2012-12-06 |
4 |
A |
$0.50 |
$50,000 |
I/I |
100,000 |
252,174 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2013-06-27 |
4 |
OE |
$0.64 |
$32,000 |
I/I |
50,000 |
302,174 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2013-10-15 |
4 |
OE |
$0.64 |
$6,400 |
I/I |
10,000 |
312,174 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2013-12-20 |
4 |
A |
$0.00 |
$0 |
I/I |
100,000 |
100,000 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2016-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
5,625 |
26,234 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2019-01-14 |
4 |
OE |
$1.50 |
$38,063 |
D/D |
25,375 |
25,375 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2020-06-30 |
4 |
A |
$0.45 |
$2,240 |
D/D |
5,000 |
30,375 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2021-04-23 |
4 |
OE |
$1.50 |
$7,500 |
D/D |
5,000 |
40,375 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2021-06-30 |
4 |
A |
$1.95 |
$9,733 |
D/D |
5,000 |
45,375 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2021-12-31 |
4 |
A |
$1.66 |
$6,005 |
D/D |
3,623 |
48,998 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2022-05-12 |
4 |
OE |
$1.00 |
$100,000 |
D/D |
100,000 |
148,998 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2022-06-30 |
4 |
A |
$0.75 |
$3,740 |
D/D |
5,000 |
153,998 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2022-08-17 |
4 |
B |
$0.17 |
$103,200 |
I/I |
600,000 |
626,234 |
0.01 |
% |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2022-12-30 |
4 |
A |
$0.09 |
$438 |
D/D |
5,000 |
158,998 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2023-06-30 |
4 |
A |
$1.59 |
$265 |
D/D |
167 |
5,466 |
0 |
- |
|
VTGN |
Vistagen Therapeutics Inc |
CHIEF EXECUTIVE OFFICER |
|
2023-12-29 |
4 |
A |
$1.72 |
$287 |
D/D |
167 |
5,633 |
0 |
- |
|
19 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|